Trial Profile
Efficacy and pharmacokinetics of a switch from a regimen consisting of emtricitabine, nevirapine and tenofovir to rilpivirine, emtricitabine and tenofovir in virologically suppressed HIV-1 infected patients.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 30 Nov 2015
Price :
$35
*
At a glance
- Drugs Emtricitabine/rilpivirine/tenofovir disoproxil fumarate (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- 16 Apr 2012 New trial record